CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
about
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive LeukemiasHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionProtein kinase CK2 and human malignant tumorsOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.Low-density crystal packing of human protein kinase CK2 catalytic subunit in complex with resorufin or other ligands: a tool to study the unique hinge-region plasticity of the enzyme without packing biasA subnanomolar fluorescent probe for protein kinase CK2 interaction studiesCell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potentialMalaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulationTargeting Pim kinases for cancer treatment: opportunities and challengesEffects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cellsIdentification of a novel function of CX-4945 as a splicing regulatorCasein kinase II inhibitor enhances production of infectious genotype 1a hepatitis C virus (H77S)A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerA chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibitionAdult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells.Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation indexAntitumoral activity of allosteric inhibitors of protein kinase CK2.Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Protein phosphatase 1 (PP1) and Casein Kinase II (CK2) regulate Ikaros-mediated repression of TdT in thymocytes and T-cell leukemia.CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.Isomeric mono-, di-, and tri-bromobenzo-1H-triazoles as inhibitors of human protein kinase CK2α.Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.Occludin S408 phosphorylation regulates tight junction protein interactions and barrier functionCK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9.Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapyMEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.Identification of signalling cascades involved in red blood cell shrinkage and vesiculation.Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsInfluence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cellsIdentification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.
P2860
Q26769590-601052D6-5064-49F7-BF87-4E5479E698E8Q26779128-BBEE95AE-C254-41B4-9746-FEB5D9945F53Q27026335-061923A3-380D-46B6-A2A4-53F4545662D7Q27332192-9311102E-71A5-40AC-B38B-CD6048073B56Q27681892-EA83100F-7AE3-4397-9648-B252CF435415Q27682639-CF778D30-CB22-45FB-88CD-A08008BAE324Q27688944-C09E4432-8E33-4AE7-ABCB-E9F491324D0BQ27973595-069D2DCA-25D7-4C4F-86E7-E8382D984AC5Q28255361-3E62EBB3-FBC4-4EFD-8C45-056FE9882830Q28485087-3195E262-0F90-47BB-97AB-915BB21747FAQ28537999-77328A7F-114F-4B40-8704-435242138C9DQ28542410-00B6076B-1B9B-4B92-870B-DFB362560DC2Q28551341-9E462B82-71B7-4D95-86F6-640ED341AB97Q28828212-7C72E992-8887-48C1-A018-15C78CEC7001Q33695967-83B37F69-E8F5-4896-BA61-9500B40AF605Q33796957-2BE0E7E4-D954-44DD-ABBA-577C55D60DDAQ33959504-49AB5FB5-B72A-405A-BB02-F628620C5CCAQ33960547-3A5FC4E7-0ED1-4D38-B73C-6CE0B12872A8Q34020978-F17A97CA-9552-4E98-A7EF-478B68C9D422Q34049848-D0CB2A17-6212-482C-904F-BC2BEFE2A3B7Q34106499-9E411E0F-4B93-466D-A9D0-44C6235D50D8Q34227776-03A1773C-3B3A-4791-BD7E-F1E2632ED19BQ34247901-BECC0662-DDD4-4E96-8AA4-558F0B1CC11CQ34265716-EEDDA838-CBA3-45EE-A408-0E0D8925D612Q34381851-C9027CE9-C3FB-435D-8B3D-F84BC69DC716Q34417563-E11FEFF6-A9D5-41D8-9FC3-E99964783D13Q34471660-A508DE6C-B8F5-4A3A-BE6B-A211CB91E3EDQ34479175-8035AAE8-855B-402C-9E8A-D0AFDC27A2B8Q34812814-07E8BCF0-E013-4B36-95A8-20C06EE07B12Q34918139-A15B00AB-3BDF-40A8-A19F-9360EE0676A5Q34984681-4ECD722A-FF27-4218-9AC5-93C9A0497B94Q35005510-C26C3111-E237-49EF-A64B-56721C7C7465Q35009302-84956510-103F-4A89-9D43-C45F022F896EQ35132090-3B3D21EC-31C9-400E-9BC9-3BD88374AF4CQ35197507-6CAE3E8B-B116-4B97-8203-A3D050BF4C05Q35423247-CFB32BFF-64B6-4D84-862E-6F753D7AFB3FQ35574674-A8656C84-9620-4157-917A-88F1DC9A1B67Q35577635-A18F1785-A27F-4215-9F40-91A82A151772Q35578724-B6FD5BCE-D740-4B74-BD65-3836AD91B60FQ35627487-CB828AA9-0849-40C1-AB17-1E8C09325ADE
P2860
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@ast
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@en
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@nl
type
label
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@ast
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@en
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@nl
prefLabel
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@ast
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@en
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@nl
P2093
P1433
P1476
CX-4945, an orally bioavailabl ...... d exhibits antitumor efficacy.
@en
P2093
Adam Siddiqui-Jain
Caroline Ho
Chris Proffitt
David M Ryckman
Denis Drygin
Fabrice Pierre
Josh Bliesath
Kenna Anderes
Mayuko Omori
Michael K Schwaebe
P304
10288-10298
P356
10.1158/0008-5472.CAN-10-1893
P407
P577
2010-12-01T00:00:00Z